BiotechTube
Pataigin

Pataigin

Cambridge, United States· Est.
pataigin.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Pataigin is a private, pre-revenue diagnostics company based in Cambridge, USA, founded in 2016 (incorporated in 2019). It is commercializing a novel microbial lipid fingerprinting technology platform to enable one-hour pathogen identification directly from clinical specimens. Its lead product, BACLIB, is currently available for Research Use Only (RUO) via an Early Access program, positioning the company in the high-growth rapid diagnostics market. The company's success hinges on translating its strong academic foundation into a clinically validated, market-leading diagnostic test.

Infectious Diseases

Technology Platform

Microbial lipid fingerprinting using MALDI-TOF mass spectrometry with a novel rapid on-target extraction method to identify pathogens and antimicrobial resistance directly from clinical specimens in one hour.

Opportunities

The global push for antimicrobial stewardship creates a massive demand for rapid diagnostics that can reduce inappropriate antibiotic use and improve sepsis outcomes.
Leveraging existing MALDI-TOF MS infrastructure in hospitals lowers the adoption barrier, positioning BACLIB as a cost-effective upgrade to current workflows.

Risk Factors

Key risks include failure to obtain regulatory clearance after costly clinical trials, technical challenges in validating a robust IVD assay across diverse sample types, and intense competition from established molecular diagnostics and larger companies with greater commercial resources.

Competitive Landscape

Pataigin competes with traditional culture-based methods, rapid molecular PCR panels (e.g., BioFire, Cepheid), and next-generation sequencing. Its differentiation is the one-hour turnaround time direct from specimen on existing MALDI-TOF platforms, but it must prove clinical utility and cost-effectiveness against entrenched, high-throughput molecular solutions.

More companies in United States →